BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ayling RM, Kok K. Fecal Calprotectin. Adv Clin Chem 2018;87:161-90. [PMID: 30342711 DOI: 10.1016/bs.acc.2018.07.005] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 14.8] [Reference Citation Analysis]
Number Citing Articles
1 Corsi F, Sorrentino L, Albasini S, Colombo F, Cigognini M, Massari A, Morasso C, Mazzucchelli S, Piccotti F, Ardizzone S, Sampietro GM, Truffi M. Circulating Fibroblast Activation Protein as Potential Biomarker in Patients With Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:725726. [PMID: 34621763 DOI: 10.3389/fmed.2021.725726] [Reference Citation Analysis]
2 Lowe DM, Smith PJ, Moreira F, Workman S, Braggins H, Koukias N, Buckland MS, Wylie P, Taylor SA, Murray CD. Chronic Granulomatous Disorder-Associated Colitis Can Be Accurately Evaluated with MRI Scans and Fecal Calprotectin Level. J Clin Immunol 2019;39:494-504. [PMID: 31172380 DOI: 10.1007/s10875-019-00651-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Gong SS, Fan YH, Han QQ, Lv B, Xu Y. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. World J Gastroenterol 2019; 25(18): 2240-2250 [PMID: 31143074 DOI: 10.3748/wjg.v25.i18.2240] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T, Motoya S, Maemoto A, Fujiya M, Ashida T, Goto M, Matsumoto T, Suzuki Y, Hamahata Y, Nakagawa T, Kato N, Kato J, Endo Y, Suzuki R, Matsuda K, Ohmiya N, Katsushima S, Hosomi S, Tarumi K, Watanabe C, Saito M, Yokoyama Y, Inaba T, Sakata Y, Hongo H, Shibuya T, Kawakami K, Kakuta Y, Irisawa A, Yoshimura N, Fukuda K, Shirai T, Ichikawa H, Nagata J, Suzuki T, Yokoyama K, Tomidokoro T, Kojima Y, Yamada M, Yamamoto H, Yamamoto T, Horiki N, Obata H, Inoue S, Tanaka S, Toyokawa T, Kunihiro M, Hisabe T, Ogata S, Takeshima F, Matsushima K, Matsuhashi N, Sakuraba H, Iwabuchi M, Tsuchiya A, Uchiyama K, Kanai T, Nakamura M, Yokoyama T, Hida N, Mitsuyama K, Osada T, Hiraoka S, Tsuzuki T, Masuo T, Hokari R, Kobayashi T, Saruta M, Araki M, Araki H, Shimizu M, Kikuchi M, Nishikawa T, Takedatsu H, Aoyagi K, Ochiai T, Toda N, Mizokami Y, Nagahori M, Matsueda K, Kino H, Kanamori A, Suzuki T, Sakurai T, Kudo M, Kitano A, Hisamatsu T, Kumagai S, Ninomiya T, Mori K, Yoshida S, Goto M. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Gastroenterology & Hepatology 2022;7:648-57. [DOI: 10.1016/s2468-1253(22)00022-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ge C, Lu Y, Shen H, Zhu L. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scand J Gastroenterol 2022;:1-12. [PMID: 34994661 DOI: 10.1080/00365521.2021.2022193] [Reference Citation Analysis]
6 Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019;56:307-20. [PMID: 31088326 DOI: 10.1080/10408363.2019.1619159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
7 Aguirre-Padilla LM, Madrid-Villanueva BE, Ugarte-Olvera ME, Alonso-Soto J. Tuberculosis and Crohn's disease - A challenging endoscopic diagnosis. A case report. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00108-0. [PMID: 34774459 DOI: 10.1016/j.rgmxen.2021.10.003] [Reference Citation Analysis]
8 Di Pierro F. Gut Microbiota Parameters Potentially Useful in Clinical Perspective. Microorganisms 2021;9:2402. [PMID: 34835527 DOI: 10.3390/microorganisms9112402] [Reference Citation Analysis]
9 Eckard AR, Hughes HY, Hagood NL, O'Riordan MA, Labbato D, Kosco JC, Scott SE, McComsey GA. Fecal Calprotectin Is Elevated in HIV and Related to Systemic Inflammation. J Acquir Immune Defic Syndr 2021;86:231-9. [PMID: 33065582 DOI: 10.1097/QAI.0000000000002538] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shokri-Afra H, Alikhani A, Moradipoodeh B, Noorbakhsh F, Fakheri H, Moradi-Sardareh H. Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms. Sci Rep 2021;11:22001. [PMID: 34753964 DOI: 10.1038/s41598-021-01231-4] [Reference Citation Analysis]
11 Zou F, Wang X, Glitza Oliva IC, McQuade JL, Wang J, Zhang HC, Thompson JA, Thomas AS, Wang Y. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 2021;9:e002058. [PMID: 33436487 DOI: 10.1136/jitc-2020-002058] [Reference Citation Analysis]
12 Rychter AM, Ratajczak AE, Szymczak-Tomczak A, Michalak M, Eder P, Dobrowolska A, Krela-Kaźmierczak I. Associations of Lifestyle Factors with Osteopenia and Osteoporosis in Polish Patients with Inflammatory Bowel Disease. Nutrients 2021;13:1863. [PMID: 34070791 DOI: 10.3390/nu13061863] [Reference Citation Analysis]
13 Lopez CA, Beavers WN, Weiss A, Knippel RJ, Zackular JP, Chazin W, Skaar EP. The Immune Protein Calprotectin Impacts Clostridioides difficile Metabolism through Zinc Limitation. mBio 2019;10:e02289-19. [PMID: 31744916 DOI: 10.1128/mBio.02289-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Heilmann RM, Guard MM, Toresson L, Unterer S, Grellet A, Grützner N, Suchodolski JS, Steiner JM. Association of clinical characteristics and lifestyle factors with fecal S100/calgranulin concentrations in healthy dogs. Vet Med Sci 2021;7:1131-43. [PMID: 33751838 DOI: 10.1002/vms3.469] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Alizadeh A, Akbari P, Garssen J, Fink-Gremmels J, Braber S. Epithelial integrity, junctional complexes, and biomarkers associated with intestinal functions. Tissue Barriers 2021;:1996830. [PMID: 34719339 DOI: 10.1080/21688370.2021.1996830] [Reference Citation Analysis]
16 Östlund I, Werner M, Karling P. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease. Scand J Gastroenterol 2021;56:38-45. [PMID: 33284639 DOI: 10.1080/00365521.2020.1854342] [Reference Citation Analysis]
17 Aksu Çerman A, Aktaş Karabay E, Kaya HE, Türe Özdemir F, Özkur E, Erdem Y, Kıvanç Altunay İ. Evaluation of fecal calprotectin as a marker of gastrointestinal inflammation in rosacea: A case-control study. Dermatol Ther 2021;34:e14946. [PMID: 33719160 DOI: 10.1111/dth.14946] [Reference Citation Analysis]
18 Sandhu K, Naik S, Ayling RM. Use of faecal immunochemical testing as an alternative to faecal calprotectin in children. Ann Clin Biochem 2021;58:230-5. [PMID: 33412889 DOI: 10.1177/0004563221989359] [Reference Citation Analysis]
19 Pero-Gascon R, Hemeryck LY, Poma G, Falony G, Nawrot TS, Raes J, Vanhaecke L, De Boevre M, Covaci A, De Saeger S. FLEXiGUT: Rationale for exposomics associations with chronic low-grade gut inflammation. Environ Int 2021;158:106906. [PMID: 34607040 DOI: 10.1016/j.envint.2021.106906] [Reference Citation Analysis]
20 Waite MMA, Langmead L, Ayling RM. Faecal calprotectin is not necessarily required as a screen for significant bowel disease in primary care. Ann Clin Biochem 2021;:45632211063458. [PMID: 34958262 DOI: 10.1177/00045632211063458] [Reference Citation Analysis]
21 Zhou W, Qiao H, Yuan W, Yao Z, Liu K, Wang J, Pang Y. Diagnostic utility of fecal calprotectin in patients presenting to the emergency department with suspected acute appendicitis. Am J Emerg Med 2020;38:2303-7. [PMID: 31780188 DOI: 10.1016/j.ajem.2019.10.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
22 Krzystek-Korpacka M, Kempiński R, Bromke MA, Neubauer K. Oxidative Stress Markers in Inflammatory Bowel Diseases: Systematic Review. Diagnostics (Basel) 2020;10:E601. [PMID: 32824619 DOI: 10.3390/diagnostics10080601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
23 Morgan RB, Shogan BD. The science of anastomotic healing. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100879] [Reference Citation Analysis]
24 Morasso C, Truffi M, Vanna R, Albasini S, Mazzucchelli S, Colombo F, Sorrentino L, Sampietro G, Ardizzone S, Corsi F. Raman Analysis Reveals Biochemical Differences in Plasma of Crohn's Disease Patients. J Crohns Colitis 2020;14:1572-80. [PMID: 32343792 DOI: 10.1093/ecco-jcc/jjaa080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Fauny M, D'Amico F, Bonovas S, Netter P, Danese S, Loeuille D, Peyrin-Biroulet L. Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. J Crohns Colitis 2020;14:688-93. [PMID: 31858121 DOI: 10.1093/ecco-jcc/jjz205] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
26 Benthem de Grave X, Saltzmann J, Laurain J, Rodriguez MA, Molist F, Dänicke S, Santos RR. Transmission of Zearalenone, Deoxynivalenol, and Their Derivatives from Sows to Piglets during Lactation. Toxins (Basel) 2021;13:37. [PMID: 33419041 DOI: 10.3390/toxins13010037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
27 Wu Y, Wang Z, Xing M, Li B, Liu Z, Du P, Yang H, Wang X. The Specific Changes of Urine Raman Spectra Can Serve as Novel Diagnostic Tools for Disease Characteristics in Patients with Crohn’s Disease. JIR 2022;Volume 15:897-910. [DOI: 10.2147/jir.s341871] [Reference Citation Analysis]
28 Akhmedov VA, Sargsyan AK, Gaus OV. Prospects for the use of biomarkers in the diagnosis of irritable bowel syndrome. jour 2020. [DOI: 10.31146/1682-8658-ecg-175-3-94-101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Traina L, Mucignat M, Rizzo R, Gafà R, Bortolotti D, Passaro A, Zamboni P. COVID-19 induced aorto duodenal fistula following evar in the so called "negative" patient. Vascular 2021;:17085381211053695. [PMID: 34919005 DOI: 10.1177/17085381211053695] [Reference Citation Analysis]
30 Baumann R, Untersmayr E, Zissler UM, Eyerich S, Adcock IM, Brockow K, Biedermann T, Ollert M, Chaker AM, Pfaar O, Garn H, Thwaites RS, Togias A, Kowalski ML, Hansel TT, Jakwerth CA, Schmidt-Weber CB. Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases. Allergy 2021;76:1010-23. [PMID: 33128851 DOI: 10.1111/all.14645] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
31 Boucard AS, Thomas M, Lebon W, Polack B, Florent I, Langella P, Bermúdez-Humarán LG. Age and Giardia intestinalis Infection Impact Canine Gut Microbiota. Microorganisms 2021;9:1862. [PMID: 34576757 DOI: 10.3390/microorganisms9091862] [Reference Citation Analysis]
32 Ojetti V, Saviano A, Covino M, Acampora N, Troiani E, Franceschi F; GEMELLI AGAINST COVID‐19 group. COVID-19 and intestinal inflammation: Role of fecal calprotectin. Dig Liver Dis 2020;52:1231-3. [PMID: 33060042 DOI: 10.1016/j.dld.2020.09.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
33 Krzystek-Korpacka M, Kempiński R, Bromke M, Neubauer K. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:E367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
34 Zerbato V, Di Bella S, Giuffrè M, Jaracz AW, Gobbo Y, Luppino D, Macor P, Segat L, Koncan R, D'Agaro P, Valentini M, Crocé LS, Ruscio M, Luzzati R. High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study. World J Gastroenterol 2021; 27(22): 3130-3137 [PMID: 34168414 DOI: 10.3748/wjg.v27.i22.3130] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Puig L. The safety of ixekizumab in psoriasis drug therapy. Expert Opinion on Drug Safety 2020;19:117-30. [DOI: 10.1080/14740338.2020.1709440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Reference Citation Analysis]
37 Zhang X, Ishikawa D, Nomura K, Fukuda N, Haraikawa M, Haga K, Shibuya T, Mita T, Nagahara A. Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis. J Clin Med 2022;11:1055. [PMID: 35207328 DOI: 10.3390/jcm11041055] [Reference Citation Analysis]
38 Suarez-Carantoña C, Rodriguez-Torres A, Viteri-Noel A, Pintado V, Garcia-Fernandez S, Mora-Pimentel D, Escudero-Sanchez R, Martin-Jusdado F, Moreno S, Cobo J. Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic Clostridioides difficile. J Clin Med 2021;10:1627. [PMID: 33921309 DOI: 10.3390/jcm10081627] [Reference Citation Analysis]
39 Szczubełek M, Pomorska K, Korólczyk-Kowalczyk M, Lewandowski K, Kaniewska M, Rydzewska G. Effectiveness of Crohn's Disease Exclusion Diet for Induction of Remission in Crohn's Disease Adult Patients. Nutrients 2021;13:4112. [PMID: 34836367 DOI: 10.3390/nu13114112] [Reference Citation Analysis]
40 Hijos-Mallada G, Velamazán R, Marti R, Chueca E, Arechavaleta S, Lué A, Gomollón F, Lanas A, Sostres C. A Patient Self-Made Point-of-Care Fecal Test Improves Diagnostic Accuracy Compared with Fecal Calprotectin Alone in Inflammatory Bowel Disease Patients. Diagnostics (Basel) 2021;11:2323. [PMID: 34943560 DOI: 10.3390/diagnostics11122323] [Reference Citation Analysis]
41 Ye X, Wang Y, Wang HHX, Feng R, Ye Z, Han J, Li L, Zeng Z, Chen M, Zhang S. Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis. Therap Adv Gastroenterol 2021;14:1756284821994741. [PMID: 33717211 DOI: 10.1177/1756284821994741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Wang X, Tang Q, Hou H, Zhang W, Li M, Chen D, Gu Y, Wang B, Hou J, Liu Y, Cao H. Gut Microbiota in NSAID Enteropathy: New Insights From Inside. Front Cell Infect Microbiol 2021;11:679396. [PMID: 34295835 DOI: 10.3389/fcimb.2021.679396] [Reference Citation Analysis]
43 Pérez de Arce E, Quera R, Beltrán CJ, Madrid AM, Nos P. Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis? Gastroenterol Hepatol 2021:S0210-5705(21)00143-6. [PMID: 34023477 DOI: 10.1016/j.gastrohep.2021.02.022] [Reference Citation Analysis]
44 Becker A, Abuazab M, Schwiertz A, Walter S, Faßbender KC, Fousse M, Unger MM. Short-chain fatty acids and intestinal inflammation in multiple sclerosis: modulation of female susceptibility by microbial products? Auto Immun Highlights 2021;12:7. [PMID: 33827656 DOI: 10.1186/s13317-021-00149-1] [Reference Citation Analysis]
45 Polkowska-Pruszyńska B, Gerkowicz A, Rawicz-Pruszyński K, Krasowska D. The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO). Diagnostics (Basel) 2020;10:E587. [PMID: 32823752 DOI: 10.3390/diagnostics10080587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]